Stock Market & Financial Investment News

News Breaks January 14, 2013 06:15 EDT CVD Covance upgraded to Buy from Neutral at Goldman Goldman upgraded Covance due to re-accelerating earnings growth and potential upside from its clinical business, among other reasons. Price target raised to $70 from $53. News For CVD From The Last 14 Days Check below for free stories on CVD the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for CVD Sign up for a free trial to see the rest of the stories you've been missing.